Abstract
Pyoderma gangrenosum is an ulcerating inflammatory condition defined pathologically by an abundance of neutrophils in the absence of infection. Often, hospital admission is necessary for rapidly progressing PG for wound care and adequate pain control. However, few large-scaled controlled studies exist examining hospitalizations for PG in the pediatric populations and the associated comorbidities. We sought to determine the prevalence, length of stay (LOS), cost of care, and any risk factors for admission and associated comorbidities in children hospitalized for PG in the U.S. Data were analyzed from the 2002 to 2012 National Inpatient Sample, including a 20% representative sample of all hospitalizations in the United States. The prevalence of hospitalization between 2002 and 2012 ranged from 2 to 11 per million hospitalized children. Hospitalization for PG was associated with older age, female gender, black race/ethnicity, the third quartile for household income, having 2–5 chronic conditions, being admitted to a micropolitan or a non-metro/micropolitan hospital and to a teaching hospital. Hospitalization with vs. without a primary diagnosis of PG was associated with significantly prolonged LOS. The total inflation-adjusted cost of care for hospitalization with a primary diagnosis of PG was $2,202,576; $200,234 per year). The geometric-mean cost of hospitalization was significantly higher in children with vs. without a primary diagnosis of PG. Children hospitalized for PG were found to have higher odds of thyroid disease, inflammatory bowel disease, hematologic malignancy, and other autoimmune disorders. While children are rarely hospitalized for PG, they have prolonged hospitalization, and clinical interventions need to be developed to prevent hospitalization for PG. Further, concomitant workup for other systemic comorbidities is also warranted at the time of diagnosis and throughout disease course.
Abbreviations
- ICD-9-CM:
-
International classification of disease 9th edition clinical modification
- PG:
-
Pyoderma gangrenosum
- NIS:
-
National (Nationwide) inpatient sample
- CI:
-
Confidence interval
- LOS:
-
Length of stay
References
Braswell SF, Kostopoulos TC, Ortega-Loayza AG (2015) Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 73(4):691–698
Kechichian E, Haber R, Mourad N, El Khoury R, Jabbour S, Tomb R (2017) Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol 56(5):486–495
Soleimani T, Sasor SE, Spera L et al (2016) Pediatric pyoderma gangrenosum: is it just big wounds on little adults? J Surg Res 206(1):113–117
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289–300
Narla S, Silverberg JI (2020) The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States. Arch Dermatol Res
Funding
This publication was made possible with support from the Agency for Healthcare Research and Quality, grant number K12 HS023011, the Dermatology Foundation.
Author information
Authors and Affiliations
Contributions
JI Silverberg had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: JI Silverberg. Acquisition of Data: JI Silverberg, S Narla. Analysis and interpretation of data: S Narla, JI Silverberg. Drafting of the manuscript: S Narla, JI Silverberg. Critical revision of the manuscript for important intellectual content: S Narla, JI Silverberg. Statistical analysis: JI Silverberg, S Narla. Obtained funding: JI Silverberg.
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Narla, S., Silverberg, J.I. The inpatient burden of pyoderma gangrenosum and associated comorbidities in children in the United States. Arch Dermatol Res 314, 613–617 (2022). https://doi.org/10.1007/s00403-021-02189-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-021-02189-z